(ARTL) Artelo Biosciences - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US04301G2012
ARTL: Cannabinoid Receptor Agonist, Cannabidiol Cocrystal, Fatty Acid Inhibitor
Artelo Biosciences, Inc. (NASDAQ:ARTL) is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments targeting lipid-signaling pathways. The companys pipeline includes three main candidates: ART27.13, a dual cannabinoid GPCR agonist in Phase 1b/2a trials for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal under investigation for anxiety, PTSD, epilepsy, and inflammatory bowel disease; and ART26.12, an FABP5 inhibitor being studied for chemotherapy-induced peripheral neuropathy, diabetic neuropathy, prostate and breast cancers, pain management, dermatologic conditions, and anxiety disorders. Originally founded as Reactive Medical, Inc. in 2011, the company rebranded as Artelo Biosciences in April 2017 and is headquartered in Solana Beach, California. Their commitment to innovation in lipid-signaling pathways positions them uniquely in the biopharma landscape.
As of the latest data, ARTL shares are trading at $0.97 with a 20-day average volume of 19,596. The stocks short-term trend indicators show a SMA20 of $1.13, SMA50 of $1.16, and SMA200 of $1.21, signaling a bearish trend. The ATR of $0.07 reflects low volatility. On the fundamental side, the company has a market cap of $3.23M and a P/B ratio of 1.14, typical for a micro-cap biotech firm in early clinical stages.
3-Month Forecast: Based on the provided data, ARTL is expected to remain in a stable but slightly bearish trend. The SMA20 and SMA50 suggest potential downside risk, with support near $0.90. The low ATR indicates minimal price fluctuations, likely confined within a $0.90-$1.10 range. Volume remains a critical factor, as low liquidity could amplify price movements. Fundamental catalysts, such as clinical trial updates, could drive short-term volatility.Additional Sources for ARTL Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ARTL Stock Overview
| Market Cap in USD | 3m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2017-11-14 |
ARTL Stock Ratings
| Growth 5y | -90.6% |
| Fundamental | - |
| Dividend | 0.0% |
| Rel. Strength Industry | -36.6 |
| Analysts | 4.5/5 |
| Fair Price Momentum | 0.56 USD |
| Fair Price DCF | - |
ARTL Dividends
No Dividends PaidARTL Growth Ratios
| Growth Correlation 3m | 5.1% |
| Growth Correlation 12m | -77.5% |
| Growth Correlation 5y | -95.6% |
| CAGR 5y | -37.80% |
| CAGR/Max DD 5y | -0.39 |
| Sharpe Ratio 12m | -0.73 |
| Alpha | -46.29 |
| Beta | 0.94 |
| Volatility | 59.17% |
| Current Volume | 11.2k |
| Average Volume 20d | 19.4k |
As of March 15, 2025, the stock is trading at USD 0.96 with a total of 11,191 shares traded.
Over the past week, the price has changed by -4.00%, over one month by -19.33%, over three months by -9.43% and over the past year by -36.00%.
No, based on ValueRay Analyses, Artelo Biosciences (NASDAQ:ARTL) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -90.61 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARTL as of March 2025 is 0.56. This means that ARTL is currently overvalued and has a potential downside of -41.67%.
Artelo Biosciences has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy ARTL.
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, ARTL Artelo Biosciences will be worth about 0.6 in March 2026. The stock is currently trading at 0.96. This means that the stock has a potential downside of -34.38%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 5.3 | 455.2% |
| Analysts Target Price | 5 | 420.8% |
| ValueRay Target Price | 0.6 | -34.4% |